ArticleNature2025
FBP1 controls liver cancer evolution from senescent MASH hepatocytes.
Erratum issuedAbstract read
In one paragraph
Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 39 papers.
0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed.
- Salvianolic acid C alleviates acute kidney injury by restoring fructose-1,6-bisphosphatase 1-mediated gluconeogenesis.Renal failure · 2026Article
- Senolytics dasatinib and quercetin in metabolic dysfunction-associated steatohepatitis: a proof-of-principle randomized, controlled trial.Nature metabolism · 2026Article
- FBP1-Mediated Compartmentalization of Glycolytic Enzyme Complexes Suppresses PKM2 Function to Ameliorate MASLD Progression.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Dysregulated mScience advances · 2026Article
- Discovery of FBP1 as novel therapeutic target and asiatic acid-hydrogen sulfide donors accelerate diabetic wound healing.Journal of advanced research · 2026Article
- TERT drives liver tumorigenesis beyond telomere elongation.Life science alliance · 2026Article
- Molecular mechanisms and pathogenesis of MASH.Nature · 2026Review
- Alcohol reshapes liver zonal plasticity and immune-metabolic reprogramming in metabolic-syndrome associated hepatocellular carcinoma.Nature communications · 2026Article
- Fibroblasts resistScience advances · 2026Article
- Metabolically and epigenetically reprogrammed splenic TRNP1Nature genetics · 2026Article
- Cellular Senescence and Aging: Mechanisms, Disease Convergence, and Therapeutic Frontiers.MedComm · 2026Review
- Metabolic Regulation of Immune Responses: Molecular Mechanisms, Diseases, and Therapeutic Targets.MedComm · 2026Review
- Fructose 1-phosphate inhibits mannose phosphate isomerase to suppress hepatocellular carcinogenesis.Signal transduction and targeted therapy · 2026Article
- THEMIS attenuates MASH by suppressing disease-associated hepatocyte induction and hepatocyte senescence in mice.The Journal of clinical investigation · 2026Article
- Global Advances in Hepatocellular Carcinoma Research and Therapy in 2025.Cancer innovation · 2026Review
- Article
- p16Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Article
- A Translational Model of MASLD-Associated HFpEF Defines Mitochondrial Dysfunction and Cardiac Plasticity During Disease Progression and Regression.bioRxiv : the preprint server for biology · 2026Article
- [Advances in basic and experimental diagnostic research on liver diseases in 2025].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
23 authors.
Li Gu *Laboratory of Gene Regulation and Signal Transduction, Departments of Pharmacology and Pathology, School of Medicine, University of California San Diego (UCSD), La Jolla, CA, USA. ligu@scu.edu.cn.ORCID 0000-0001-5812-9024
Yahui Zhu *School of Medicine, Chongqing University, Chongqing, China. zhuyahui861106@foxmail.com.ORCID 0000-0002-8138-0011
Shuvro P NandiDepartment of Cellular and Molecular Medicine, UCSD, La Jolla, CA, USA.ORCID 0000-0003-4855-4697
Maiya LeeLaboratory of Gene Regulation and Signal Transduction, Departments of Pharmacology and Pathology, School of Medicine, University of California San Diego (UCSD), La Jolla, CA, USA.
Kosuke WatariLaboratory of Gene Regulation and Signal Transduction, Departments of Pharmacology and Pathology, School of Medicine, University of California San Diego (UCSD), La Jolla, CA, USA.ORCID 0000-0003-0260-2323
Breanna BarengLaboratory of Gene Regulation and Signal Transduction, Departments of Pharmacology and Pathology, School of Medicine, University of California San Diego (UCSD), La Jolla, CA, USA.
Masafumi OhiraLaboratory of Gene Regulation and Signal Transduction, Departments of Pharmacology and Pathology, School of Medicine, University of California San Diego (UCSD), La Jolla, CA, USA.ORCID 0000-0003-0775-3390
Yuxiao LiuLaboratory of Gene Regulation and Signal Transduction, Departments of Pharmacology and Pathology, School of Medicine, University of California San Diego (UCSD), La Jolla, CA, USA.
Sadatsugu SakaneDivision of Endocrinology & Metabolism, UCSD, La Jolla, CA, USA.ORCID 0000-0002-6306-4621
Rodrigo CarlessiCurtin Medical School, Curtin Health Innovation Research Institute, Curtin University, Bentley, Western Australia, Australia.ORCID 0000-0003-0038-7391
Consuelo SaucedaDepartment of Pharmacology, UCSD, La Jolla, CA, USA.
Debanjan DharDepartment of Medicine, UCSD, La Jolla, CA, USA.
Souradipta GangulyDepartment of Medicine, UCSD, La Jolla, CA, USA.
Mojgan HosseiniDepartment of Pathology, UCSD, La Jolla, CA, USA.
Marcos G TenecheSanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.ORCID 0000-0003-4785-7987
Peter D AdamsSanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.ORCID 0000-0002-0684-1770
David J GonzalezDepartment of Pharmacology, UCSD, La Jolla, CA, USA.
Tatiana KisselevaDivision of Endocrinology & Metabolism, UCSD, La Jolla, CA, USA.
Liver Cancer Collaborative
Janina E E Tirnitz-ParkerCurtin Medical School, Curtin Health Innovation Research Institute, Curtin University, Bentley, Western Australia, Australia.ORCID 0000-0002-3558-5892
M Celeste SimonAbramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0001-9106-447X
Ludmil B AlexandrovDepartment of Cellular and Molecular Medicine, UCSD, La Jolla, CA, USA.ORCID 0000-0003-3596-4515
Michael KarinLaboratory of Gene Regulation and Signal Transduction, Departments of Pharmacology and Pathology, School of Medicine, University of California San Diego (UCSD), La Jolla, CA, USA. karinoffice@ucsd.edu.ORCID 0000-0002-2758-6473
Funding
VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DIANE M SIMEONE · 1985 to 2026
$124.9MUC San Diego Clinical and Translational Research InstituteKL2TR001444 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DEPP, COLIN A. · 2015 to 2024
$15.4MProject 4: Interrogating and harnessing age-related IFN signaling and innate immunity in HCC prevention and therapyP01AG073084 · NIA · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI PETER D. ADAMS, GERALD SHADEL · 2021 to 2026
$13.6MSan Diego Digestive Diseases Research CenterP30DK120515 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Bernd G. Schnabl · 2019 to 2026
$10.8MMetabolic Tumor Suppressors in Renal Cancer: Unprecedented Roles in Disease ProgressionR35CA220483 · NCI · UNIVERSITY OF PENNSYLVANIA · PI M. CELESTE SIMON · 2017 to 2026
$9.4MRole of hypernutrition and metabolic stress in non-alcoholic steatohepatitis (NASH) driven hepatocellular carcinoma (HCC)P01CA281819 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI Pablo Tamayo · 2024 to 2026
$9.2MInactivation of Hepatic Stellate Cells During Reversal of Liver FibrosisR01DK099205 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BRENNER, DAVID A., KISSELEVA, TATIANA · 2014 to 2025
$4.8MControl of Lipogenesis and Hepatic Steatosis by Caspase-2R01DK120714 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Michael Karin · 2019 to 2026
$4.0MThe NRF2-FBP1 crossregulatory loop and the control of healthy and diseased liver metabolismR01DK133448 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Michael Karin, Jun Hee Lee · 2022 to 2026
$3.6MDetecting Mutational Signatures of Environmental Mutagens in Heathy Individuals for Personalized Cancer PreventionR01ES032547 · NIEHS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ALEXANDROV, LUDMIL B · 2021 to 2025
$3.4MHighly penetrant and immunogenic mouse models of non-viral HCC that are suitable for evaluation of immune checkpoint inhibitorsR01CA234128 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KARIN, MICHAEL · 2019 to 2023
$2.7MDissecting the Intracellular and Extracellular Role of TREM2 in the Pathogenesis of Non-Alcoholic Steatohepatitis.R01DK137061 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Debanjan Dhar · 2023 to 2026
$2.6MNCATS NIH HHS KL2 TR001444NCI NIH HHS P01 CA281819NCI NIH HHS P30 CA023100NCI NIH HHS R01 CA234128NCI NIH HHS R01 CA269919NCI NIH HHS R01 CA281784NCI NIH HHS R35 CA220483NIA NIH HHS P01 AG073084NIDDK NIH HHS P30 DK120515NIDDK NIH HHS R01 DK099205NIDDK NIH HHS R01 DK120714NIDDK NIH HHS R01 DK133448NIDDK NIH HHS R01 DK133930NIDDK NIH HHS R01 DK137061NIEHS NIH HHS R01 ES030993NIEHS NIH HHS R01 ES032547NIH HHS S10 OD032398
Abstract
Hepatocellular carcinoma (HCC) originates from differentiated hepatocytes undergoing compensatory proliferation in livers damaged by viruses or metabolic-dysfunction-associated steatohepatitis (MASH)
Indexed as
Carcinoma, HepatocellularCellular SenescenceFructose-BisphosphataseHepatocytesLiver NeoplasmsAnimalsCell Line, TumorCell ProliferationDNA DamageDNA MethylationFatty LiverHumansMaleMiceMutationNF-E2-Related Factor 2FBP1 protein, humanFructose-BisphosphataseNFE2L2 protein, humanNF-E2-Related Factor 2Proto-Oncogene Proteins c-aktTumor Suppressor Protein p53
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.